With Dr. Ziering serving as principal investigator of the study, Histogen’s Hair Stimulating Complex (HSC) is currently under evaluation and development as a progressive new injectable that promotes hair regrowth. HSC is the first bioactive compilation of WNT proteins and their cofactors that have been naturally stabilized and cited for hair follicle growth and development.
HSC represents a potentially momentous new treatment option for Ziering Medical’s patients and for millions suffering from hair loss. Researchers estimate that only 2 to 7% of people who endure hair loss worldwide actually seek pharmacological or medical treatment for their condition due to the lack of choice in effective options. These statistics hold true for the more than 87 million Americans with the same condition.
The HSC pilot clinical trial of 24 subjects, which included a double-blind placebo-controlled environment, showed significant statistics in increased hair thickness, hair density, and hair count at the end of twelve weeks. Researchers observed additional hair growth at the end of twelve months after only having administered one treatment at baseline to each subject.
While additional tests and clinical evaluations continue to ensure the efficacy and safety of HSC, the combination of growth factors and protein in its formula have been shown to not only generate new follicle formations, but also to activate resting hair follicles.
After clinical trials in Singapore in 2011 and plans for pan-Asian approval in 2014, Dr. Ziering looks forward to American approval of the product in 2015.